AWMSG issues Final Appraisal Recommendation on eplerenone (Inspra®) in patients with NYHA class II heart failure and left ventricular systolic dysfunction

Source: All Wales Medicines Strategy Group (AWMSG) Area: Evidence > Drug Specific Reviews In its Final Appraisal Recommendation, the All Wales Medicines Strategy Group (AWMSG) is of the opinion that eplerenone (Inspra®) tablets may be an appropriate treatment option within NHS Wales, in addition to standard optimal therapy, to reduce the risk of cardiovascular mortality and morbidity in adult patients with New York Heart Association (NYHA) class II (chronic) heart failure and left ventricular systolic dysfunction (LVEF ? 30%).
Source: NeLM - Cardiovascular Medicine - Category: Cardiology Source Type: news